๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Acute Lymphoblastic Leukemia
Clinical trial register · China

Acute Lymphoblastic Leukemia Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 9 Suzhou 8 Hangzhou 5 Tianjin 4 Chongqing 4
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou9 Suzhou8 Hangzhou5 Tianjin4 Chongqing4
All 27 locations
Target enrolment
to

Acute Lymphoblastic Leukemia trials in China

30 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
NCT07751588Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
25
Tianjin
2026-07-11
Not yet open
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
228
Tianjin
2026-06-01
Not yet open
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
NCT07575412Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
180
Suzhou
2026-06
Not yet open
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
NCT07562568Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
160
Suzhou
2026-06
Recruiting
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
NCT07454226Ph-Like, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
92
Tianjin
2026-05-30
Not yet open
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
NCT07483749Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
The Children's Hospital of Zhejiang University School of Medicine
Observational
400
Hangzhou, Ningbo
2026-03-25
By invitation
The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia
NCT07515430Acute Lymphoblastic Leukemia
Sun Yat-sen University
Observational
138
Guangzhou
2026-02-01
Recruiting
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
NCT07284927Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
DrugLV009
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
10
Suzhou
2025-12-03
Recruiting
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
NCT07203352Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Phase 3
154
Guangzhou
2025-10-01
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
NCT07763054Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Observational
30
Hainan
2025-08-01
Recruiting
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
NCT07072494Acute Lymphoblastic Leukemia
Zhujiang Hospital
Phase 1/2
30
Guangzhou
2025-07-19
Recruiting
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
NCT06985485Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
The First Affiliated Hospital of Soochow University
Phase 2
26
Suzhou
2025-05-17
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
NCT06816134Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
The First Affiliated Hospital of Soochow University
Phase 2
48
Suzhou
2025-01-30
Recruiting
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
NCT06718244Acute Lymphoblastic Leukemia
Ruijin Hospital
Phase 2
20
Shanghai
2024-12-10
Recruiting
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
NCT06452732Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Peking University People's Hospital
Observational
283
Beijing
2024-11-01
Recruiting
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
NCT06752785Acute Lymphoblastic Leukemia
Guangzhou Women and Children's Medical Center
Phase 1
10
Guangzhou
2024-10-01
Recruiting
Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
NCT06659653Acute Lymphoblastic Leukemia
Tan Jie
Phase EARLY_PHASE1
18
Jinzhou
2024-05-24
Recruiting
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
NCT07584889B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase 1/2
10
Shenzhen
2024-04-20
Recruiting
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
NCT06220487Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL
Nanfang Hospital, Southern Medical University
Phase 2
67
Guangzhou
2024-02-01
Recruiting
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
NCT05579132Acute Lymphoblastic Leukemia
MSD R&D (China) Co., Ltd.
Phase 1/2
203
Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu
2022-11-01
Recruiting
CAV Regimen for R/R Ph- B-ALL
NCT05657652Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
36
Suzhou
2022-10-01
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
50
Taiyuan
2022-09-07
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Recruiting
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
NCT04532281Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
Zhejiang University
Phase EARLY_PHASE1
120
Hangzhou
2020-11-01
Recruiting
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
NCT04532203Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Zhejiang University
Phase EARLY_PHASE1
72
Hangzhou
2020-11-01
Active, closed
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Otsuka Beijing Research Institute
Phase 2
93
Hefei, Guangzhou, Wuhan, Changsha, Suzhou, Shenyang, Jinan, Taiyuan
2020-07-09
Recruiting
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
NCT04227015Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
He Huang
Phase EARLY_PHASE1
72
Hangzhou
2020-01-08
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/acute-lymphoblastic-leukemia

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies listing the condition Acute Lymphoblastic Leukemia.

How many Acute Lymphoblastic Leukemia trials are recruiting in China?

21 of the 30 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Acute Lymphoblastic Leukemia), 30 studies
PhaseStudiesRecruitingShare
Phase 29530%
Observational5216.7%
Phase 14213.3%
Phase EARLY_PHASE14413.3%
Not applicable3310%
Phase 1/23310%
Phase 2/3113.3%
Phase 3113.3%

Most active sponsors

Lead sponsors with the most studies (Acute Lymphoblastic Leukemia)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Soochow University53
Institute of Hematology & Blood Diseases Hospital, China32
Nanfang Hospital, Southern Medical University22
Ruijin Hospital21
Zhejiang University22
Chongqing Precision Biotech Co., Ltd11
Guangzhou Women and Children's Medical Center11
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine11
He Huang11
Hebei Senlang Biotechnology Inc., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.